LONDON, UNITED KINGDOM--(Marketwired - Apr 29, 2016) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today announced that April 2016 saw the company sell and ship 425 kilograms of product, representing approximately $60,000 in revenues. In addition, since January, Plandaí announced that customers have released to market a total of ten new branded consumer products that contain Phytofare®, which are being sold in Australia, Western Europe and Africa. Products containing Phytofare® should be on shelves in United States as early as May.

Callum Cottrell-Duffield, Vice President of Sales and Marketing for Plandaí Biotechnology, commented, "We are pleased that our month over month sales volumes continue to grow. While the numbers are not yet staggering, we are nearing operational break-even and expect to achieve this short-term goal in the coming few months. As it stands, sales in April alone nearly equaled the total sales volume for the entire first quarter. As we enter new markets, including the United States, South America and Asia, we anticipate that sales will continue expanding as market acceptance has been very favorable."

Addressing the benefits of Phytofare® over competing products, Mr. Cottrell-Duffield added, "Phytofare® is one of the few nutraceutical products that is backed by human clinical trials and the only one to our knowledge that compares its bioavailability against that of a generic extract. In the case of green tea, numerous studies have shown that its catechins have tremendous potential health benefits as an antioxidant, thermogenesis stimulator, and as an anti-viral. Being able to scientifically prove that Phytofare® can deliver ten times more of the active ingredients to your system, and then have those ingredients remain in the blood plasma at therapeutic levels for over 24 hours, is a seen as a huge advantage by our customers. They believe, and we heartily agree, that consumers will see the difference and start demanding that their supplements actually deliver on their claims."

"Our goal by the end of 2016," Mr. Cottrell-Duffield continued, "is to have monthly sales of two metric tons, at which point the Senteeko factory will be positioned to increase production so that sales can increase to four tons per month. As we start selling more Phytofare Ph2, which is Phytofare® entrapped in Pheroid®, this volume can further double, giving us the potential for eight tons per month."

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop highly phyto-available™ extracts. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare® extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutriceutical, anti-aging, and pharmaceutical. For more information, please visit

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at

Contact Information:

Hannah Merrill